Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.

导出 OA

翻译打印收藏纠错

作者： Stefano,Molica ^[1] ; Constantine,Tam ^[2] ; David,Allsup ^[3] ; Aaron,Polliack ^[4]

作者单位： Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull HU16 5JQ, UK. ^[1] Alfred Hospital, Melbourne, VIC 3004, Australia. ^[2] Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull HU16 5JQ, UK.;Centre of Biomedicine, Hull York Medical School, University of Hull, Hull HU16 5JQ, UK. ^[3] Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. ^[4]

关键词 BTK inhibitors CLL chronic lymphocytic leukemia efficacy safety zanubrutinib

DOI 10.3390/cancers15143737

PMID 37509398

发布时间 2024-09-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交